IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.342
+0.009 (2.67%)
Nov 21, 2024, 10:56 AM EST - Market open
IGC Pharma Revenue
IGC Pharma had revenue of $412.00K in the quarter ending September 30, 2024, with 41.58% growth. This brings the company's revenue in the last twelve months to $1.18M, down -11.91% year-over-year. In the fiscal year ending March 31, 2024, IGC Pharma had annual revenue of $1.35M with 47.64% growth.
Revenue (ttm)
$1.18M
Revenue Growth
-11.91%
P/S Ratio
19.50
Revenue / Employee
$17,657
Employees
67
Market Cap
26.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 1.35M | 434.00K | 47.64% |
| Mar 31, 2023 | 911.00K | 514.00K | 129.47% |
| Mar 31, 2022 | 397.00K | -501.00K | -55.79% |
| Mar 31, 2021 | 898.00K | -3.17M | -77.95% |
| Mar 31, 2020 | 4.07M | -1.04M | -20.41% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DarioHealth | 23.05M |
| Surrozen | 10.00M |
| Lipocine | 7.92M |
| Marker Therapeutics | 5.40M |
| GeoVax Labs | 3.09M |
| Daré Bioscience | 1.88M |
| Pluri | 598.00K |
| GlycoMimetics | 10.00K |
IGC News
- 7 days ago - IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline - Accesswire
- 15 days ago - IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies - Accesswire
- 5 weeks ago - IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1 - Accesswire
- 7 weeks ago - IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge - Accesswire
- 2 months ago - IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment - Business Wire
- 2 months ago - IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease - Business Wire
- 3 months ago - IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease - Business Wire
- 3 months ago - IGC Pharma Reports First Quarter Fiscal 2025 Results - Business Wire